Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 16/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 16/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 11/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039168 | 0.86 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA7GAAALPG | |
| SCHEMBL700923 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA7GAAALPG | |
| SCHEMBL7040448 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNA7GAAALPG | |
| SCHEMBL7040400 | 0.78 | CHRNA7 (0.58) | CHRNB2CHRNA4CHRNA7GAAALPG | |
| Methane SCHEMBL9568421 | 0.78 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA7GAAALPG | |
| SCHEMBL7045702 | 0.75 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNA7GAAALPG | |
| SCHEMBL7042274 | 0.73 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNA7GAAALPG | |
| SCHEMBL7047422 | 0.72 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA7GAAALPG | |
| SCHEMBL7045708 | 0.72 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA7GAAALPG | |
| SCHEMBL12255499 | 0.71 | GBA1 (0.45) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | SCHMITT JEFFREY DANIEL (US) | 2003-03-06 | — | — | US | disclosed |
| US-6432975-B1 | AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1053236-A1 | PYRDIYL-BRIIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000034276-A1 | PYRIDYL-BRIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | CHRNG, CHRNB1, CHRNA1 | CHRNB2 9/4885CHRNA4 13/4885CHRNA7 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.